Intergenerational transmission of functional gastrointestinal disorders: Children of IBS patients versus parents of children with IBS, functional dyspepsia, and functional abdominal pain

2003 ◽  
Vol 124 (4) ◽  
pp. A533 ◽  
Author(s):  
Arlene Caplan ◽  
Philippe Lambrette ◽  
Lucie Joly ◽  
Mickael Bouin ◽  
Michel Boivin ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Intergenerational Transmission ◽  
Functional Dyspepsia ◽  
Functional Gastrointestinal Disorders ◽  
Gastrointestinal Disorders ◽  
Functional Abdominal Pain

scholarly journals Functional Abdominal Pain of Children: Therapy with Bacillus Coagulans GBI-30, 6086 and Insight into Its Probiotic Properties

2021 ◽  
pp. 19-27
Author(s):  
Vishnu Kumar Tandon ◽  
Trayambak Dutta ◽  
R. Ezhil Arasan
Keyword(s):  
Abdominal Pain ◽  
Digestive Enzymes ◽  
Clinical Evidence ◽  
Functional Gastrointestinal Disorders ◽  
Bacillus Coagulans ◽  
Gastrointestinal Disorders ◽  
Probiotic Properties ◽  
Functional Abdominal Pain ◽  
Insight Into

Background: Probiotics are effective in the treatment of functional gastrointestinal disorders in adults but there is lack of enough clinical evidence in children. Aim: To evaluate effectiveness of Bacillus Coagulans GBI-30, 6086 along with digestive enzymes in the treatment of childhood functional abdominal pain (FAP). Methods: Children with FAP, based on the Rome IV criteria (n = 95, aged 5-16 years), received Bacillus Coagulans GBI-30, 6086 along with digestive enzymes from a commercially available preparation - Tummysoft® for three weeks. Treatment response was assessed by improvement in the Quality of Life in Reflux and Dyspepsia Questionnaire (QOLRAD) score and Global Overall Symptom (GOS) scale. Results: Patients diagnosed with FAP upon receiving a 3-week treatment with Bacillus Coagulans GBI-30, 6086 along with digestive enzymes, registered statistically significant improvement in both QOLRAD (Baseline, 30.27 ± 5.95; 10th Day: 108.39 ± 7.06; 21st day: 173.71 ± 6.71, P=0.00) and GOS scale (Baseline, 3.10 ± 0.37; 10th Day: 2.15 ± 0.73; 21st day: 1.00 ± 0.00, P = 0) signifying the efficacy of the probiotic in FAP. Conclusion: Bacillus Coagulans GBI-30, 6086 along with digestive enzymes from a commercially available preparation - Tummysoft® was found to be effective in the treatment of childhood functional abdominal pain (FAP).

scholarly journals The Role of Disaccharidase Deficiencies in Functional Abdominal Pain Disorders—A Narrative Review

Nutrients ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1835 ◽  
Author(s):  
Mora Puertolas ◽  
Amanda Fifi
Keyword(s):  
Abdominal Pain ◽  
Scientific Literature ◽  
Diarrheal Disease ◽  
Functional Gastrointestinal Disorders ◽  
Pain Disorder ◽  
Gastrointestinal Disorders ◽  
Functional Disorders ◽  
Functional Abdominal Pain ◽  
Pediatric Populations

Disaccharidase deficiencies are reportedly underdiagnosed in pediatric populations. Though typically thought to cause diarrheal disease, they can also be a cause of abdominal pain and dyspepsia, and patients diagnosed with these functional disorders may actually have associated enzyme deficiencies. While the effects of lactose deficiency have been widely studied, sucrase, maltase, and isomaltase are less frequently considered when approaching a patient with an apparent functional abdominal pain disorder. This review seeks to provide an up-to-date narrative on the current scientific literature on the possible role of sucrase, maltase, and isomaltase deficiency in pediatric functional gastrointestinal disorders.

scholarly journals Functional gastrointestinal disorders in children: agreement between Rome III and Rome IV diagnoses

2021 ◽  
Author(s):  
Desiree F. Baaleman ◽  
Carlos A. Velasco-Benítez ◽  
Laura M. Méndez-Guzmán ◽  
Marc A. Benninga ◽  
Miguel Saps
Keyword(s):  
Diagnostic Criteria ◽  
Functional Dyspepsia ◽  
Functional Gastrointestinal Disorders ◽  
Functional Constipation ◽  
Final Analysis ◽  
Gastrointestinal Disorders ◽  
Rome Iii ◽  
Sample Characteristics ◽  
Irritable Bowel ◽  
Rome Iv

AbstractTo evaluate the agreement between the Rome III and Rome IV criteria in diagnosing pediatric functional gastrointestinal disorders (FGIDs), we conducted a prospective cohort study in a public school in Cali, Colombia. Children and adolescents between 11 and 18 years of age were given the Spanish version of the Questionnaire on Pediatric Functional Gastrointestinal Disorders Rome III version on day 0 and Rome IV version on day 2 (48 h later). The study protocol was completed by 135 children. Thirty-nine (28.9%) children were excluded because of not following the instructions of the questionnaire. The final analysis included data of 96 children (mean 15.2 years old, SD ± 1.7, 54% girls). Less children fulfilled the criteria for an FGID according to Rome IV compared to Rome III (40.6% vs 29.2%, p=0.063) resulting in a minimal agreement between the two criteria in diagnosing an FGID (kappa 0.34, agreement of 70%). The prevalence of functional constipation according to Rome IV was significantly lower compared to Rome III (13.5% vs 31.3%, p<0.001), whereas functional dyspepsia had a higher prevalence according to Rome IV than Rome III (11.5% vs 0%).Conclusion: We found an overall minimal agreement in diagnosing FGIDs according to Rome III and Rome IV criteria. This may be partly explained by the differences in diagnostic criteria. However, limitations with the use of questionnaires to measure prevalence have to be taken into account. What is Known:• The Rome IV criteria replaced the previous Rome III criteria providing updated criteria to diagnose functional gastrointestinal disorders (FGIDs).• Differences found between Rome IV and historic Rome III FGID prevalence may have been affected by changes in prevalence over time or differences in sample characteristics. What is New:• We found a minimal agreement between Rome III and Rome IV FGID diagnosis, especially in the diagnoses of functional constipation, irritable bowel syndrome, and functional dyspepsia.• The minimal agreement may be partly explained by changes in diagnostic criteria, but limitations with the use of questionnaires to measure prevalence have to be taken into account.

Calprotectin (S100 A8/A9) and TNF-alpha in differential diagnosis of chronic abdominal pain in children

2017 ◽  
Vol 53 (1) ◽  
pp. 5-10
Author(s):  
Stanisław Pieczarkowski ◽  
Kinga Kowalska-Duplaga ◽  
Andrzej Wędrychowicz ◽  
Krzysztof Fyderek ◽  
Przemko Kwinta ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Functional Gastrointestinal Disorders ◽  
Fecal Calprotectin ◽  
Chronic Abdominal Pain ◽  
Tnf Alpha ◽  
Gastrointestinal Disorders ◽  
Control Group ◽  
Healthy Children ◽  
Inflammatory Bowel

<i>Introduction:</i> Chronic abdominal pain in children is a very frequent and sometimes challenging diagnostic issue. Differential diagnosis in that cases is difficult and often connected with numerous, time-consuming, expensive, and frequently stressful diagnostic studies. The aim of the study was to establish whether fecal calprotectin concentration (FCC) and TNF-alpha may be useful in children with chronic abdominal pain to differentiate between inflammatory bowel disease (IBD), other inflammatory gastrointestinal disorders, and functional gastrointestinal disorders. Methods. The study included patients (median age 13 years), who were assigned to functional gastrointestinal disorders group (n=33); inflammatory gastrointestinal disorders other than IBD (n=71), children with IBD (n=37) and 22 healthy children served as a control group. The concertation of FCC and TNF-alpha in stool samples was measured using ELISA. <i>Results:</i> In healthy children and in children with functional disorders FCCs were below 100 μg/g. In patients with IBD FCCs and TNF-alpha were markedly elevated as compare to children with functional gastrointestinal disorders, however using ROC discrimination of IBD patients was significantly better using FCC than TNF-alpha. <i>Conclusion:</i> FCC is better test for differentiation between IBD, other inflammatory gastrointestinal disorders, and functional gastrointestinal disorders as compare to TNF-alpha concentration in stool. FCC as screening test in patients with chronic abdominal pain should allow to diminish unnecessary diagnostic in cases of functional gastrointestinal disorders.

Sign in / Sign up

Export Citation Format

Share Document